Abstract
We develop and apply a simplified SIR model to current data for the 2019-2020 SARS-Cov-2/Covid-19 pandemic for the United Kingdom (UK) and eight European countries: Norway, Sweden, Denmark, the Netherlands, France, Germany, Italy and Spain. The most important result of the model was the identification and segregation of pandemic characteristics into two distinct groups: those that are invariant across countries, and those that are highly variable. Amongst the former is the infective period TL, which was very similar for all countries, with an average value of 
days. The other invariants were TR, the average time between contacts and R = NC, the average number of contacts while infective. We find 
days and 
. In contrast to these invariants, there was a highly variable time lag TD between the peak in the daily number of infected individuals and the peak in the daily number of deaths, ranging from a low of TD = 4 days for Italy and Denmark, to a high of TD = 17 for Norway. The mortality probability among identified cases was also highly variable, ranging from low values 3.5%, 5% and 5% for Norway, Denmark and Germany respectively to high values of 18%, 18% and 20% for France, Sweden and the UK respectively. Our analysis predicts that the number of deaths per million population until the pandemic ends (defined as when the daily number of deaths is less than 5) will be lowest for Norway (45 deaths/million) and highest for the United Kingdom (628 deaths/million). Finally, we observe a small but detectable effect of average temperature on the probability α of infection in each contact, with higher temperatures associated with lower infectivity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GB was partly supported by grants from M2GEN/ORIEN, DoD/ KRCP (KC180159) and NIH/NCI (1R01CA243547-01A1). He thanks Professors Pablo Tamayo and Jill Mesirov for their kind hospitality at UC San Diego during his sabbatical year 2019-2020 when this work was done.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used were all from public databases. No IRB approval was necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Gyan Bhanot, PhD, 136 Frelinghuysen Road, Busch Campus, Rutgers University, Piscataway, NJ 08854, USA, Phone: (848) 391-7508, Fax: (732) 235-5331, Email: gyanbhanot{at}gmail.com
Charles DeLisi, PhD, 24 Cummington Mall, Boston University, Boston, Ma 02215, Phone 617 875 5138, Email: DeLisi{at}bu.edu
Data Availability
The data used in this paper were all derived from public sources. Links to these data are included in the paper. The Matlab codes used to analyze the data along with all data files will be provided on request - email: gyanbhanot{at}gmail.com.
